Product Information
EVEROLIMUS 1 MG TABLET is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $5.2530 per EA under NDC 00054060421. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Apr 12, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/1
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054060421
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
EVEROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA206133FDA Approved
4/12/2018
TE Code
AB
On Market Since
11/18/2021
Pharmacological Classes
Price Statistics
The NADAC for EVEROLIMUS 1 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 68.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.2530 per EA |
|---|---|
| All-time high | $16.6894 (May 15, 2024) |
| All-time low | $5.2530 (Sep 23, 2026) |
| 52-week high | $14.3925 |
| 52-week low | $5.2530 |
| Median price | $13.2650 |
| Average price | $12.1264 |
| Largest weekly change | -31.0% (Jul 17, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Everolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of EVEROLIMUS 1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for EVEROLIMUS 1 MG TABLET, manufactured by Hikma Pharmaceuticals USA Inc., is $5.2530 per EA (NDC 00054060421), effective Sep 30, 2026.
How has the price of EVEROLIMUS 1 MG TABLET changed over time?
Over the history we have for it, the NADAC for EVEROLIMUS 1 MG TABLET has declined 68.5%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for EVEROLIMUS 1 MG TABLET?
Since Apr 17, 2024, the NADAC for EVEROLIMUS 1 MG TABLET has ranged from a low of $5.2530 (Sep 23, 2026) to a high of $16.6894 (May 15, 2024), with a median of $13.2650 per EA.
Are there cheaper alternatives to EVEROLIMUS 1 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as EVEROLIMUS 1 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures EVEROLIMUS 1 MG TABLET?
EVEROLIMUS 1 MG TABLET (NDC 00054060421) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.